Your browser doesn't support javascript.
loading
Metronidazole, acyclovir and tetrahydrobiopterin may be promising to treat COVID-19 patients, through interaction with interleukin-12.
Farasati Far, Bahareh; Bokov, Dmitry; Widjaja, Gunawan; Setia Budi, Hendrik; Kamal Abdelbasset, Walid; Javanshir, Shahrzad; Seif, Farhad; Pazoki-Toroudi, Hamidreza; Dey, Sanjay Kumar.
Afiliação
  • Farasati Far B; Heterocyclic Chemistry Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, Iran.
  • Bokov D; Institute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russian Federation.
  • Widjaja G; Laboratory of Food Chemistry, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russian Federation.
  • Setia Budi H; Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.
  • Kamal Abdelbasset W; Department of Oral Biology, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, Indonesia.
  • Javanshir S; Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia.
  • Seif F; Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt.
  • Pazoki-Toroudi H; Heterocyclic Chemistry Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, Iran.
  • Dey SK; Department of Immunology & Allergy, Academic Center for Education, Culture, and Research, Tehran, Iran.
J Biomol Struct Dyn ; 41(10): 4253-4271, 2023 Jul.
Article em En | MEDLINE | ID: mdl-35446232

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Metronidazol Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 / Metronidazol Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article